<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>272</ReferenceId>
        <DateLastUpdated>2020-09-30-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12502822</PubmedId>
            <Abstract>Ebola virus causes lethal hemorrhagic fever in humans, but currently there are no effective vaccines or antiviral compounds for this infectious disease. Passive transfer of monoclonal antibodies (MAbs) protects mice from lethal Ebola virus infection (J. A. Wilson, M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart, Science 287:1664-1666, 2000). However, the epitopes responsible for neutralization have been only partially characterized because some of the MAbs do not recognize the short synthetic peptides used for epitope mapping. To identify the amino acids recognized by neutralizing and protective antibodies, we generated a recombinant vesicular stomatitis virus (VSV) containing the Ebola virus glycoprotein-encoding gene instead of the VSV G protein-encoding gene and used it to select escape variants by growing it in the presence of a MAb (133/3.16 or 226/8.1) that neutralizes the infectivity of the virus. All three variants selected by MAb 133/3.16 contained a single amino acid substitution at amino acid position 549 in the GP2 subunit. By contrast, MAb 226/8.1 selected three different variants containing substitutions at positions 134, 194, and 199 in the GP1 subunit, suggesting that this antibody recognized a conformational epitope. Passive transfer of each of these MAbs completely protected mice from a lethal Ebola virus infection. These data indicate that neutralizing antibody cocktails for passive prophylaxis and therapy of Ebola hemorrhagic fever can reduce the possibility of the emergence of antigenic variants in infected individuals.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>1069-74</ArticlePages>
            <ArticleTitle>Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Takada</LastName>
                    <ForeName>Ayato</ForeName>
                </Author>
                <Author>
                    <LastName>Feldmann</LastName>
                    <ForeName>Heinz</ForeName>
                </Author>
                <Author>
                    <LastName>Stroeher</LastName>
                    <ForeName>Ute</ForeName>
                </Author>
                <Author>
                    <LastName>Bray</LastName>
                    <ForeName>Mike</ForeName>
                </Author>
                <Author>
                    <LastName>Watanabe</LastName>
                    <ForeName>Shinji</ForeName>
                </Author>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>Hiroshi</ForeName>
                </Author>
                <Author>
                    <LastName>McGregor</LastName>
                    <ForeName>Martha</ForeName>
                </Author>
                <Author>
                    <LastName>Kawaoka</LastName>
                    <ForeName>Yoshihiro</ForeName>
                </Author>
            </Authors>
            <Affiliations>Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Japan.</Affiliations>
            <ArticleChemicalList>Amino Acids;Antibodies, Monoclonal;Epitopes;Glycoproteins;Viral Proteins;secreted glycoprotein, Ebola virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Amino Acids(chemistry); Animals; Antibodies, Monoclonal(administration &amp; dosage; immunology); Cell Line; Epitopes(chemistry); Fluorescent Antibody Technique; Glycoproteins(chemistry; genetics; immunology); Humans; Immunization, Passive; Mice; Molecular Sequence Data; Neutralization Tests; Recombination, Genetic; Sequence Homology, Amino Acid; Vesicular stomatitis Indiana virus(genetics; immunology); Viral Proteins</ArticleMeshHeadingsList>
            <Journal>
                <Volume>77</Volume>
                <Issue>2</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Ebola virus discontinuous epitope 1</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>H549</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AEK25495.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>186538</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5</LocationOfData>
                <EpitopeId>149582</EpitopeId>
                <ReferenceRegion>H549</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was deduced.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 3 and 4</LocationOfData>
                        <BCellId>1850860</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of recombinant vesicular stomatitis virus (VSV) containing GP-encoding gene from Ebola virus species Reston at a limited level.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>133/3.16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAC54891.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>186539</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <BCellId>1850861</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of recombinant vesicular stomatitis virus (VSV) containing GP-encoding gene from virus species Ivory Coast at a limited level.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>133/3.16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAB37093.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>186541</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <BCellId>22538</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of recombinant vesicular stomatitis virus (VSV) containing GP-encoding gene from Ebola virus species Sudan at a limited level.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>133/3.16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAC54882.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>186540</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1850978</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>5 weeks</Age>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Purified Immunoglobulin</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>133/3.16</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG1</TransferredAntibodyHeavyChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Mus musculus BALB/c were adoptively transferred with Purified Immunoglobulin.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>598</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Adoptive transfer of the epitope specific mAb protected mice from infection with Ebola virus strain Mayinga (Zaire, 1976).</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>128952</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1850971</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of Ebola Zaire virus, strain Mayinga.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>133/3.16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Zaire ebolavirus - Mayinga</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>128952</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1850868</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb recognized a fragment from position 521 to 560 of Zaire GP by using neutralization the infectivity of recombinant vesicular stomatitis virus (VSV) containing a series of chimeric proteins with GPs from the Zaire and Reston species.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>133/3.16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QDEGAAIGLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQ</LinearSequence>
                                        <StartingPosition>521</StartingPosition>
                                        <EndingPosition>560</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AEK25495.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2, 3 and 4</LocationOfData>
                        <BCellId>22350</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of recombinant vesicular stomatitis virus (VSV) containing GP-encoding gene from species Zaire. The epitope was deduced by loss of reactivity when VSV expressed GP with the epitopic residue mutated, as found in escape mutants.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>133/3.16</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AEK25495.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Ebola virus discontinuous epitope 2</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>R134, F194, L199</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AEK25495.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>186538</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5</LocationOfData>
                <EpitopeId>149583</EpitopeId>
                <ReferenceRegion>R134, F194, L199</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was deduced.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1850976</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>5 weeks</Age>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Purified Immunoglobulin</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>226/8.1</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG1</TransferredAntibodyHeavyChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Mus musculus BALB/c were adoptively transferred with Purified Immunoglobulin.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>598</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Adoptive transfer of the epitope specific mAb protected mice from infection with Ebola virus strain Mayinga (Zaire, 1976).</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>128952</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2, 3 and 4</LocationOfData>
                        <BCellId>22539</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of recombinant vesicular stomatitis virus (VSV) containing GP-encoding gene from species Zaire. The epitope was deduced by loss of reactivity when VSV expressed GP with the epitopic residue mutated, as found in escape mutants.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>226/8.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AEK25495.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1850975</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb recognized fragments from position 1 to 232 and 1 to 560 of Zaire GP by using neutralization the infectivity of recombinant vesicular stomatitis virus (VSV) containing a series of chimeric proteins with GPs from the Zaire and Reston species.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>226/8.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYQATGFGTNETEY</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>232</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AEK25495.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11276</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>22353</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AEK25495.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <DoseSchedule>2 doses were administered at intervals of 2 weeks, and 1 booster 1 month later.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were described in the cited reference: Takada, A. et al. 2001. J. Virol. 75: 2324-2330. [PMID: 11160735].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized the infectivity of Ebola Zaire virus strain Mayinga.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>226/8.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Zaire ebolavirus strain Mayinga</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>128952</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

